ReviewSeminars in oncology2015
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Review in Seminars in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.Journal for immunotherapy of cancer · 2019Trial
- Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.Vaccines · 2026Article
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.Human vaccines & immunotherapeutics · 2023Article
- Advances of mRNA vaccine in tumor: a maze of opportunities and challenges.Biomarker research · 2023Review
- Neoantigens and their potential applications in tumor immunotherapy.Oncology letters · 2022Review
- Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies.Vaccines · 2021Review
- Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.Frontiers in pharmacology · 2021Review
- The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.Cancer immunology, immunotherapy : CII · 2020Article
- Nanoparticle cancer vaccines: Design considerations and recent advances.Asian journal of pharmaceutical sciences · 2020Review
- Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020Review
- Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.Frontiers in immunology · 2020Review
- Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.Frontiers in immunology · 2020Article
- Personalized cancer vaccines: adjuvants are important, too.Cancer immunology, immunotherapy : CII · 2018Review
- Next Generation Cancer Vaccines-Make It Personal!Vaccines · 2018Review
- Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?Frontiers in immunology · 2018Review
- Dendritic cell-based immunotherapy.Cell research · 2017Review
- Dendritic cell vaccines for melanoma: past, present and future.Melanoma management · 2016Review
- A Perspective of Immunotherapy for Prostate Cancer.Cancers · 2016Review
- Harnessing the immune system to improve cancer therapy.Annals of translational medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies, there is renewed enthusiasm for optimizing cancer vaccines for use to prevent recurrence in early-stage cancers and/or to combine with other immune therapies for therapy of advanced cancers. Future advancements in vaccine therapy will involve the identification and selection of effective antigen formulations, optimization of adjuvants, dendritic cell (DC) activation, and combination therapies. In this summary we present the current practice, the broad collection of challenges, and the promising future directions of vaccine therapy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.